- Corporate Officers - C
- Curran Terrie
Insider Trading History of Curran Terrie
The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Curran Terrie since 2017.
This trader's CIK number is 1690298.
At the time of last reporting, Curran Terrie was the Director of Arcutis Biotherapeutics, Inc.. (stock ticker symbol ARQT).
Also see all insider trading activities at Arcutis Biotherapeutics, Inc..
Note that in the past
Curran Terrie also reported insider trading activities as an insider of the following companies:
Yearly summary of insider trading at Phathom Pharmaceuticals, Inc. (PHAT) by Curran Terrie
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2024 | PHAT | 0 | $0 | 50,699 | $550,210 | 0 | $0 |
| 2023 | PHAT | 12,919 | $101,026 | 5,821 | $47,732 | 0 | $0 |
| 2022 | PHAT | 20,500 | $151,843 | 3,052 | $29,298 | 0 | $0 |
| 2021 | PHAT | 0 | $0 | 11,513 | $502,657 | 11,513 | $80,015 |
Yearly summary of insider trading at Myovant Sciences Ltd. (MYOV) by Curran Terrie
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2021 | MYOV | 0 | $0 | 53,358 | $1,337,876 | 53,358 | $408,187 |
Yearly summary of insider trading at Celgene Corp /de/ (CELG) by Curran Terrie
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2019 | CELG | 0 | $0 | 11,338 | $1,114,015 | 6,063 | $262,485 |
| 2018 | CELG | 0 | $0 | 0 | $0 | 5,000 | $0 |
| 2017 | CELG | 0 | $0 | 1,727 | $248,498 | 1,765 | $0 |
Yearly summary of insider trading at Arcutis Biotherapeutics, Inc. (ARQT) by Curran Terrie
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2024 | ARQT | 0 | $0 | 8,687 | $94,236 | 0 | $0 |
Insider trading activities at 4 companies by Curran Terrie:
1. Phathom Pharmaceuticals, Inc. (PHAT)
2. Myovant Sciences Ltd. (MYOV)
3. Celgene Corp /de/ (CELG)
4. Arcutis Biotherapeutics, Inc. (ARQT)
Table 1. Insider trading of Phathom Pharmaceuticals, Inc. (PHAT) by Curran Terrie
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2024-07-15 | PHAT | Sale | 33,848 | 11.72 | 396,698 |
| 2024-03-22 | PHAT | Sale | 16,851 | 9.11 | 153,512 |
| 2023-04-06 | PHAT | Buy | 12,919 | 7.82 | 101,026 |
| 2023-01-20 | PHAT | Sale | 5,821 | 8.20 | 47,732 |
| 2022-11-21 | PHAT | Sale | 1,526 | 9.60 | 14,649 |
| 2022-11-21 | PHAT | Sale | 1,526 | 9.60 | 14,649 |
| 2022-05-13 | PHAT | Buy | 20,500 | 7.41 | 151,843 |
| 2021-03-22 | PHAT | Option Ex | 11,513 | 6.95 | 80,015 |
| 2021-03-22 | PHAT | Sale | 11,513 | 43.66 | 502,657 |
Table 2. Insider trading of Myovant Sciences Ltd. (MYOV) by Curran Terrie
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2021-09-09 | MYOV | Option Ex | 4,850 | 7.65 | 37,102 |
| 2021-09-09 | MYOV | Sale | 4,850 | 25.58 | 124,062 |
| 2021-09-01 | MYOV | Option Ex | 11,373 | 7.65 | 87,003 |
| 2021-09-02 | MYOV | Option Ex | 37,135 | 7.65 | 284,082 |
| 2021-09-01 | MYOV | Sale | 11,373 | 25.00 | 284,325 |
| 2021-09-02 | MYOV | Sale | 37,135 | 25.03 | 929,489 |
Table 3. Insider trading of Celgene Corp /de/ (CELG) by Curran Terrie
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2019-09-18 | CELG | Sale | 11,338 | 98.25 | 1,114,015 |
| 2019-09-18 | CELG | Option Ex | 4,500 | 58.33 | 262,485 |
| 2019-05-02 | CELG | Option Ex | 1,563 | .00 | 0 |
| 2018-12-16 | CELG | Option Ex | 2,500 | .00 | 0 |
| 2018-05-04 | CELG | Option Ex | 2,500 | .00 | 0 |
| 2017-12-19 | CELG | Option Ex | 1,765 | .00 | 0 |
| 2017-09-25 | CELG | Sale | 1,727 | 143.89 | 248,498 |
Table 4. Insider trading of Arcutis Biotherapeutics, Inc. (ARQT) by Curran Terrie
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2024-11-11 | ARQT | Sale | 8,687 | 10.85 | 94,236 |
Insider trading activities including stock purchases, stock sales, and option exercises
listed in the above table cannot be completely guaranteed as to their accuracy.
For more information regarding the trades made by Curran Terrie
(Director of Arcutis Biotherapeutics, Inc. at the time of this reporting) see
the Securities and Exchange Commission (SEC) website.